BOULDER, Colo.–(BUSINESS WIRE)–miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, announced today that it is the recipient of the University of Colorado (CU) Technology Transfer Office Bioscience Company of the Year award. The award will be conferred this evening at the CU Technology Transfer Annual Awards Banquet in Denver.
“We are honored to be recognized by the University of Colorado with this award, and pleased to be working with them on the Beta Blocker Effects on Remodeling and Gene Expression (BORG) study”
miRagen Therapeutics and CU signed research and licensing agreements in October 2010 launching their collaboration on microRNA therapeutics discovery and development. The collaboration is focused on microRNA profiling of a human heart failure study conducted at CU.